0000000001314959

AUTHOR

Francesco Maranta

showing 4 related works from this author

Treatment of diabetes and heart failure: Facts and hopes.

2022

Heart FailureHopepreventionDiabetes MellitusHumansCardiology and Cardiovascular MedicineInternational journal of cardiology
researchProduct

Filling the gap between Guidelines and Real World in the cardiovascular approach to the diabetic patients: the need for a call to action

2020

Blood GlucoseAmerican diabetes associationmedicine.medical_specialtybusiness.industryLow density lipoprotein cholesterolCardiovascular outcome trials Cardiovascular prevention Cardiovascular risk Diabetes mellitus type 2 Glucose-lowering drugs Therapeutical targets Blood Glucose Humans Hypoglycemic Agents Cardiovascular Diseases Diabetes Mellitus Type 2 Sodium-Glucose Transporter 2 InhibitorsCall to actionProprotein Convertase Subtilisin/Kexin 9Diabetes Mellitus Type 2Cardiovascular preventionCardiovascular DiseasesHumansHypoglycemic AgentsMedicineCardiology and Cardiovascular MedicinebusinessIntensive care medicineSodium-Glucose Transporter 2 InhibitorsGlycated haemoglobin
researchProduct

Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 D…

2020

Introduction: Liraglutide has several non-glycemic effects, including those on plasma lipids and lipoproteins, contributing to its cardiovascular benefit; however, the exact underlying mechanisms remain unclear. We investigated a novel anti-atherogenic effect of liraglutide in a real-world prospective study on patients with type 2 diabetes (T2DM). Methods: Sixty-two patients with T2DM (31 men, 31 women; mean age ± standard deviation 61 ± 9 years) naïve to incretin-based therapies were treated with liraglutide (1.2 mg/day) as add-on therapy to metformin (1500–3000 mg/day) for 4 months. Laboratory analyses included the assessment of lipoprotein subclass profile by gel electrophoresis (Lipopri…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismLipoproteinsIncretin030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineCardiovascular risk Carotid intima-media thickness Lipoproteins Liraglutide Small dense low-density lipoproteinsType 2 diabetesInternal medicineDiabetes mellitusInternal MedicinemedicineCarotid intima-media thicknessSmall dense low-density lipoproteinsOriginal ResearchLiraglutidebusiness.industryType 2 diabetesLiraglutidemedicine.diseaseCardiovascular riskMetforminEndocrinologyIntima-media thicknessbusinessBody mass indexLipoproteinmedicine.drug
researchProduct

Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients With Type 2 D…

2020

Article full text The article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days. The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite). © The authors, CC-BY-NC 2020.

researchProduct